Longitudinal outcomes of iStent inject with cataract surgery compared with cataract surgery alone: real-world data from the Fight Glaucoma Blindness registry.

Purpose: To compare combined phacoemulsification and iStent inject with phacoemulsification alone.

Setting: Fight Glaucoma Blindness (FGB) registry, Sydney, Australia.

Design: Prospective observational registry study.

Methods: Eyes that had combined phacoemulsification with iStent inject (iStent group), n = 1257 were compared with eyes that had phacoemulsification only (cataract alone, n = 163). The primary outcome was percentage of eyes achieving >20% intraocular pressure (IOP) reduction from baseline 12 months postoperatively. Secondary outcomes included mean IOP and medication reduction, adverse events, and secondary procedures.

Results: At 12 months, the percentage of eyes achieving >20% reduction of IOP was significantly higher in the iStent group compared with the cataract-alone group (40.9% vs 30.1% P < .001). Adverse events occurred at a low rate in both groups, and secondary IOP-lowering procedures were significantly less frequent in the iStent group compared with cataract alone.

Conclusions: Real-world outcomes from the FGB registry at 12 months show that phacoemulsification combined with iStent inject has a higher efficacy and reduced need for secondary IOP-lowering surgery compared with phacoemulsification alone.